Examples of successful active targeting have been demonstrated with nanocarriers conjugated with an anti-transferrin receptor single-chain antibody fragment designed to target cancer cells by binding to the transferrin receptor (TfR) [141, 142]. This evidence concerns the gene TFRC and cancer.